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Background: Risk prediction models capitalizing on genetic and environmental information hold great promise for
individualized disease prediction and prevention. Nevertheless, linking the genetic and environmental risk predictors
into a useful risk prediction model remains a great challenge. To facilitate risk prediction analyses, we have
developed a graphical user interface package, Bridge.
Results: The package is built for both designing and analyzing a risk prediction model. In the design stage, it
provides an estimated classification accuracy of the model using essential genetic and environmental information
gained from public resources and/or previous studies, and determines the sample size required to verify this
accuracy. In the analysis stage, it adopts a robust and powerful algorithm to form the risk prediction model.
Conclusions: The package is developed based on the optimality theory of the likelihood ratio and therefore
theoretically could form a model with high performance. It can be used to handle a relatively large number of
genetic and environmental predictors, with consideration of their possible interactions, and so is particularly useful
for studying risk prediction models for common complex diseases.
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The translation of human genome discoveries into health
practice represents one of the major challenges in the
coming decades [1,2]. The use of emerging genetic know-
ledge for early disease prediction, prevention and phar-
macogenetics will advance future genomic medicine and
lead to more effective prevention and treatment strategies
[3]. Among those, disease prediction based on genetic and
environmental information is the first step in translating
genomics into health [4]. It assesses an individual’s risk of
future disease, so that early preventive interventions can
be adopted to reduce morbidity and mortality [5]. For this
reason, studies to assess the combined role of genetic and
environmental information in early disease prediction rep-
resent a high priority, as manifested in multiple risk pre-
diction studies now underway [6-12].
The yield from these studies can be enhanced by
adopting powerful and computationally efficient study
design and analytic tools [13]. We have previously de-
veloped an optimal ROC curve (O-ROC) method to
quickly evaluate new genetic and environmental findings* Correspondence: qlu@epi.msu.edu
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reproduction in any medium, provided the orfor potential clinical practice by designing a new risk
prediction model, estimating its classification accuracy,
and calculating the sample size needed for evaluating
the model [14].
If, in the design stage, a proposed risk prediction model
appears to be superior to existing models, or if it reaches a
desired accuracy level, it may worth developing further for
clinical use. To evaluate the risk prediction model on
a study sample, we developed a forward ROC curve
(F-ROC) method [15]. F-ROC builds on the optimality
theory of the likelihood ratio [16], and is thus powerful for
risk prediction analysis. It adopts a stepwise selection
algorithm to efficiently deal with a large number of predic-
tors and their possible high-order interactions.
To facilitate designing and analyzing risk prediction
models, we have implemented the above two methods
into the graphical user interface (GUI) software, Bridge.
Bridge is comprised of two modules, Test Design and
Test Build. The O-ROC approach has been imple-
mented in the Test Design module, for designing a risk
prediction model. The Test Design module uses the es-
sential information (e.g., allele frequencies) of risk pre-
dictors from previously published studies or publically
available resources to design a risk predictive model, cal-
culating its estimated accuracy and the required sampled. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proach has been built into the Test Build module. The
Test Build module is developed for risk prediction mo-
deling on known risk predictors, as well as for high-
dimensional risk prediction based on a large number of
potential risk predictors. Bridge is freely accessible on-
line at https://www.msu.edu/~qlu/Software.html.
Implementation
R is open-source software used for statistical computing
and graphics. With many built-in statistic functions and
excellent scientific graphing capacity, R is now one of
the most popularly used statistical software. Although R
is widely used in statistics and related fields, it has a li-
mited graphic interface, which makes it difficult for new
R users. Bridge uses an R graphic user interface (GUI),
providing an intuitive and interactive visualization ex-
perience for users. Instead of writing code in the R con-
sole window, which could be less convenient for new
users, the user-friendly interface of Bridge allows users
to load the datasets and run the program easily by sim-
ply clicking either the options from the menu or the but-
tons from the toolbar. Moreover, for users who prefer to
use R console, Bridge also provides the access of its
functions through R console. In this paper, we give an
overview of the package. A detailed description of instal-
lation and use of the package can be found in the soft-
ware vignette.
Bridge is comprised of two independent modules, Test
Design and Test Build, for the design and construction
of a risk prediction model, respectively. The Test Design
module serves as a tool for designing a risk prediction
study. Given the disease prevalence of a disease of inter-
est and essential information of the known risk predic-
tors (e.g., relative risks) from previous studies and/or
public resources, the Test Design module plots an esti-
mated receiver operating characteristic (ROC) curve of
the proposed predictive model, so that users can easily
visualize the estimated discriminating ability of the
model. If the model reaches desired level of discrimina-
ting ability and worth further investigation, a power ana-
lysis can be conducted to make sure sufficient power of
the study. Given the power and type I error, the required
sample size can be determined by the Test Design mo-
dule to further investigate the proposed model and verify
of its classification accuracy.
At least two strategies can be used to select single-
nucleotide polymorphisms (SNPs) for designing a risk
prediction model. One strategy is to include only disease-
susceptibility SNPs that have been replicated in multiple
studies and the other is to include as much potentially
disease-susceptibility SNPs as possible into the model.
Each strategy has its own advantages and disadvantages.
Given the limited number of SNPs identified for most ofcommon complex diseases and their small effect sizes, a
risk prediction model formed by the former strategy likely
has a low AUC value but could have robust performance
across different studies. The later strategy could result a
risk prediction model with high accuracy, especially when
gene-gene interactions exist. Nevertheless, the formed risk
prediction model tends to be less stable.
If data is collected to investigate the proposed risk pre-
diction model, we can then use the Test Build module of
Bridge to form and evaluate the proposed model. The Test
Build module can be used to assess combined effect of
known risk predictors (i.e., those identified from previous
association studies) in disease prediction, with the consid-
eration of possible high-order interactions. In addition to
risk prediction on known risk predictors, the Test Build
module also allows the users to explore a large ensemble
of potential risk predictors and their interactions for im-
proved disease prediction. This strategy is particular useful
for complex diseases where a majority of the genetic and
environmental risk predictors are unknown. For this strat-
egy, the potentially disease-susceptibility predictors can be
chosen based on both biology knowledge and statistical
evidence. For instance, we can follow a simple strategy
previously used to evaluate different sets of SNPs based
on their marginal p-values (i.e., 10-1, 10-2 ,…, 10-8) [8,17].
The Test Buildmodule has a built-in forward selection al-
gorithm to handle a large set of predictors. The algorithm
is capable of searching for important risk predictors and
interactions from a large number of environmental and
genetic predictors to further improve the risk prediction
model.
In addition, the Test Build module has a build-in func-
tion for dealing with missing data and provides options for
model building and validation (e.g., an option to control the
maximum number of risk predictors to be included in
the model). The Test Build module uses k-fold cross-
validation to provide internal validation, and can also pro-
vide external validation if an independent data is available.
The summary results (e.g., the AUC values) for the risk pre-
diction models built on the training and validation datasets
are summarized in the Bridge output window. Users can
also view the proposed model via ROC-curve plots and tree
structure plots. The detailed selection process is available
under the Test Build. Results tab in the output area.
Results and discussion
We used an empirical study of Crohn’s disease (CD) as an
example to illustrate how to use Bridge to design and form
a risk prediction model.
Use the Test Design module to design a risk prediction
model
For simplicity, we used three well-replicated CD genetic
variants, rs3828309, rs4613763 and rs11465804, to design
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tion from the Test Design menu, we entered the disease
prevalence (ρ = 0.0004) and genotype frequencies of three
markers information obtained from a previous study (see
Additional file 1). Note that if such information is not
available, other information (e.g., relative risk and popula-
tion frequency) can also be used. By clicking on the Run
command from the Test Design menu, the program esti-
mated that the 3-locus CD risk prediction model had an
AUC value of 0.61. Suppose that we are interested in
knowing whether the accuracy of the model is significant
above the level of 0.60, the Test Design module can also
calculate the sample size needed to test this hypothesis.
Assuming a type I error of 0.05, a power of 0.95, and an
equal number of cases and controls, 8257 cases and 8257
controls were required to verify that the proposed modelFigure 1 A screen shot of the Test Design Module. (A) is the interactive
viewing results, (C) is the tree area for displaying data and results, and (D)had an AUC value above 0.60. The detailed results related
to this analysis were displayed in the Design Results tab
under the Output area. The ROC curve for the estimated
risk prediction model could also be viewed by clicking on
the Plot ROC Curve option from the Test Design menu
(Figure 1).
Use the Test Build module to form a risk prediction
model
In order to further investigate the proposed 3-locus pre-
diction model, we conducted a risk prediction study by
using the case–control samples from the Wellcome Trust
Crohn’s disease genome-wide association study. From the
available 500k SNPs, we selected these 3 CD-related SNPs,
rs3828309, rs4613763 and rs11465804, and formed a
3-locus model using the Test Build module. We firstarea for entering and viewing data, (B) is the output area for
is the estimated ROC curve for the CD risk prediction model.
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3340 individuals (see Additional file 2) was used for model
building, and the second dataset with 1670 individuals
was used for model validation (see Additional file 3). With
the completion of data loading, samples in both datasets
could be viewed in the Build.Dataset Tables and Build.
validaDataset Tables under the Input area. Using the
samples from the first dataset (i.e., the training samples),
we formed a 3-locus model with a fitted AUC value of
0.60. The model was further validated in the second data-
set, which attained a predicted AUC value of 0.60. To
visualize the formed risk prediction models, the ROC
curves could be plotted by using the Plot ROC curve op-
tion from the Test Build menu. The detailed results of
the model selection were summarized in the Test Build.
Results tab under the Output area. In the analysis,
rs3828309, rs4613763 and rs11465804 were sequentially
entered into the model. In the first step, the module
selected rs3828309, and split the samples into two dis-
tinct risk groups, a high risk group and a low riskFigure 2 A screen shot of the Test Build Module. (A) is the ROC curve
curve of the CD model based on the validation dataset, and (C) is the treegroup, comprising samples with different genotypes of
rs3828309. In the sequential steps, it added new markers
into the model, and gradually divided samples into more
distinct risk groups. The selection process continued until
a 3-locus model had been reached. The details of the
model building process could be visualized via the tree
structure plot under Clusters.Plot of Tree area (Figure 2).
Note that, the risk prediction analysis could also be per-
formed under R console. The detailed description of using
the functions in R console could be found in the software
vignette.
The above analysis was limited to 3 well-established
CD SNPs. In order to consider additional predictors to
further improve the 3-locus model, we extended the
analysis to 29 potential CD-related SNPs. Using the
Wellcome Trust CD dataset (see Additional files 4 and
5), the Test Build module identified 5 SNPs and formed
a five-locus model with an AUC value of 0.63. The five-
locus model was further validated in the testing sample
with a predicted AUC value of 0.62. By considering 29of the CD prediction model built on the initial dataset, (B) is the ROC
plot of the risk groups identified by the Test Build module.
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able to select 2 additional predictor, rs3764147 and
rs4263839, into the model, and further improved the
accuracy of the CD risk prediction model.
Conclusion
With increasing genetic findings from large-scale genetic
studies, risk prediction studies are being conducted to
evaluate the role of potential genetic and environmental
predictors in early disease prediction. While there is
increasing interest in such risk prediction research, new
bioinformatics tools have not been well developed for this
emerging area of research. We developed a GUI package,
Bridge, to facilitate risk prediction modeling. The software
will help an investigator design a study to evaluate a new
risk prediction model. It could also be used to form a new
risk prediction model based upon multiple genetic and
environmental risk predictors, with the consideration
of possible interactions. Bridge is developed based on a
graphical user interface, which can be easily accessed by
basic science and clinical researchers.
Availability and requirements
Project name: Bridge package, Project home page: https://
www.msu.edu/~qlu/Software.html. Operating system(s):
Linux, Windows, Mac OS X, Programming language: R,
Other requirements: R (≥3.0.0), License: GNU GPL, Any
restrictions to use by non-academics: none except those
posed by the license.
Additional files
Additional file 1: The example data for the Test Design module.
The data includes three CD-related SNPs, rs3828309, rs4613763 and
rs11465804 and their genotypic frequencies.
Additional file 2: The training data for the Test Build module. This
case–control dataset includes three CD-related SNPs for 3340 individuals,
1323 of which are cases. This dataset was used to build the prediction
model.
Additional file 3: The validation data for the Test Build module. This
case–control dataset includes three CD-related SNPs for 1670 individuals,
684 of which are cases. This dataset was used for model validation.
Additional file 4: The second training data for the Test Build
module. This case–control dataset includes 29 CD-related SNPs for 3340
individuals, 1323 of which are cases. This dataset was used to build the
prediction model.
Additional file 5: The second validation data for the Test Build
module. This case–control dataset includes 29 CD-related SNPs for 1670
individuals, 684 of which are cases. This dataset was used for model
validation.
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